Form 4: Verve Therapeutics Director Sheila Mikhail Granted Stock Options

Verve Therapeutics, Inc. director Sheila Mikhail was granted 42,200 stock options with an exercise price of $5.73 as part of the company's 2021 Stock Incentive Plan and director compensation program.

Summary

• Sheila Mikhail, a Director of Verve Therapeutics, Inc. (VERV), was granted 42,200 stock options.
• The options have an exercise price of $5.73 per share.
• The grant date for these options was June 5, 2025.
• These options were issued under the company's 2021 Stock Incentive Plan as part of its director compensation program.
• The vesting commencement date is the grant date, and all shares underlying the option will vest upon the earlier of the one-year anniversary of the vesting commencement date or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
• The options expire on June 4, 2035.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it reflects standard corporate governance and compensation practices, aligning director interests with shareholders. It is a routine, expected event with no negative surprises.

Positives

• The grant of stock options aligns the interests of Director Sheila Mikhail with those of shareholders, as the options gain value only if the stock price increases above the exercise price.
• This is a standard component of director compensation, indicating a structured approach to attracting and retaining qualified board members.
• The options were granted under an existing and approved plan (2021 Stock Incentive Plan), demonstrating adherence to established corporate governance practices.

Negatives

• The issuance of new stock options, upon exercise, can lead to a minor dilutive effect on existing shareholders, though this is typical for equity compensation plans.

Risks

• No specific risks are detailed in this Form 4 filing beyond the inherent risks associated with equity compensation (e.g., potential dilution upon exercise).

Future Outlook

The granted stock options will vest upon the earlier of the one-year anniversary of the June 5, 2025 grant date or immediately prior to the first annual meeting of stockholders occurring after the grant date, contingent on Sheila Mikhail's continued service as a director.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to incentivize long-term performance and align director interests with shareholder value creation. This filing reflects a routine compensation event within Verve Therapeutics' established governance framework.

Comparison to Industry Standards

• The practice of granting stock options to non-employee directors is a standard compensation mechanism across publicly traded companies, particularly in the high-growth biotechnology sector.
• While specific grant sizes and exercise prices vary based on company size, stage, and individual director roles, the structure of this grant under a pre-approved stock incentive plan is consistent with typical corporate governance and compensation practices observed in companies like Moderna (MRNA) or CRISPR Therapeutics (CRSP) for their non-executive directors, aiming to align long-term incentives.

Corporate Governance

Related Party Transactions

• The grant of 42,200 stock options to Sheila Mikhail, a director of Verve Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: Potential minor dilution upon exercise of options, but also potential benefit from improved director alignment and long-term performance incentives.
• Employees: No direct impact mentioned, but reflects the company's overall compensation philosophy which may influence employee equity programs.

Next Steps

• Vesting of the 42,200 stock options for Sheila Mikhail, which will occur upon the earlier of June 5, 2026 (one-year anniversary of grant) or immediately prior to the first annual meeting of stockholders after the grant date, subject to continued service.

Key Dates

Keywords

Verve Therapeutics, VERV, SEC Form 4, Stock Option Grant, Director Compensation, Equity Compensation, Insider Transaction, Sheila Mikhail, 2021 Stock Incentive Plan